119例艾滋病患者并发药物性肝损伤的临床特点及预后分析

杨君洋; 齐唐凯; 张仁芳; 刘莉; 沈银忠; 纪永佳; 卢洪洲

doi:10.3969/j.issn.1001-5256.2017.08.026

119例艾滋病患者并发药物性肝损伤的临床特点及预后分析

DOI: 10.3969/j.issn.1001-5256.2017.08.026

1. 温州医科大学
2. 复旦大学附属上海市公共卫生临床中心

基金项目:

国家自然科学基金面上项目(81571977)；

详细信息

中图分类号: R512.91;R575
计量
- 文章访问数: 2290
- HTML全文浏览量: 58
- PDF下载量: 444
- 被引次数: 0
出版历程
- 收稿日期: 2017-01-18
- 出版日期: 2017-08-20

Clinical features and prognosis of AIDS complicated by drug-induced liver injury: an analysis of 119 cases

Wenzhou Medical University

Research funding:

摘要

摘要:
目的探讨AIDS患者发生药物性肝损伤（DILI）的临床特点及预后。方法收集2014年1月-2015年12月在上海市公共卫生临床中心感染一科确诊为AIDS并符合DILI诊断的患者119例。分析患者用药情况、CD4+T淋巴细胞计数、临床表现、肝脏生化指标、治疗方法、肝损伤持续时间及预后,并对患者DILI进行分型及分级,观察不同药物导致的DILI对肝生化指标的影响。计量资料2组间比较采用Wilcoxon秩和检验,多组间比较采用Kruskal-Wallis H检验;计数资料组间比较采用χ2检验。结果 58例已接受高效抗逆转录病毒治疗患者的肝损伤分级（χ2=15.756,P<0.001）、TBil水平（Z=-3.466,P=0.010）及Alb水平（Z=-1.968,P=0.049）明显高于61例未接受高效抗逆转录病毒治疗的患者;已明确导致患者DILI的药物种类中8例为抗真菌药物、41例为抗细菌药物、18例为抗结核药物、24例为抗病毒药物,抗结核药物较其他3种药物所致DILI患者的TBil水平更高（H=12.804,P=0....
- 获得性免疫缺陷综合征 /
- 药物性肝损伤 /
- 预后
Abstract:
Objective To investigate the clinical features and prognosis of AIDS patients complicated by drug-induced liver injury ( DILI) . Methods A total of 119 patients who were diagnosed with AIDS in First Department of Infectious Diseases in Shanghai Public Health Clinical Center from January 2014 to December 2015 and met the diagnostic criteria for DILI were enrolled. The clinical data including medications, CD4~+T lymphocyte count, clinical manifestations, liver biochemical parameters, therapies, duration of liver injury, and prognosis were analyzed, and DILI type and classification were determined for all patients. The influence of DILI caused by different drugs on liver biochemical parameters was analyzed. The Wilcoxon rank sum test was used for comparison of continuous data between two groups and the Kruskal-Wallis H test was used for comparison between multiple groups; the chi-square test was used for comparison of categorical data between groups. Results The 58 patients who received highly active antiretroviral treatment ( HAART) had significantly higher grade of liver injury ( χ2= 15. 756, P < 0. 001) and levels of total bilirubin ( TBil) ( Z =-3. 466, P = 0. 010) and albumin ( Alb) ( Z =-1. 968, P = 0. 049) than the 61 patients who did not. Among the patients who had a clear cause of DILI, 8 had DILI caused by antifungal drugs, 41 had DILI caused by antibacterial drugs, 18 had DILI caused by antitubercular agents, and 24 had DILI caused by antiviral drugs; the patients with DILI caused by antitubercular agents had a significantly higher level of TBil than those with DILI caused by other three types of drugs ( H = 12. 804, P = 0. 005) , the patients with DILI caused by antibacterial drugs and antitubercular agents had a significantly lower level of Alb than those with DILI caused by the other two types of drugs ( H = 14. 236, P = 0. 003) , and the patients with DILI caused by antitubercular agents and antiviral drugs had a significantly higher grade of liver injury than those with DILI caused by the other two types of drugs ( χ2= 16. 373, P = 0. 008) . The hepatocellular injury-type patients had a shorter length of hospital stay ( χ2= 8. 046, P = 0. 045) .A high level of alkaline phosphatase and a low level of alanine aminotransferase indicated a longer length of hospital stay ( Z =-2. 943 and-2. 592, both P < 0. 05) . Conclusion AIDS patients are given various drugs and have a high incidence rate of DILI. HARRT can aggravate liver injury, but it does not significantly affect patients' prognosis. Liver function examination should be performed regularly during clinical medication to know the state of liver inflammation and reduce the incidence rate of DILI in AIDS patients.
- acquired immunodeficiency syndrome /
- drug-induced liver injury /
- prognosis

HTML全文

参考文献(13)

[1]Drug-induced liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association.Guidelines for the management of drug-induced liver injury[J].J Clin Hepatol, 2015, 31 (11) :1752-1769. (in Chinese) 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].临床肝胆病杂志, 2015, 31 (11) :1752-1769.

[2]KONTORINIS N, TERICH DT.Toxicity of non-nucleoside analogue reverse transcriptase inhibitors[J].Semin Liver Dis, 2003, 23 (2) :173-182.

[3]RODRIGUEZ-ROSADO R, GARCIA-SAMANIEGO J, SORIANO V.Hepatotoxicity after introduction of highly active antiretroviral therapy[J].AIDS, 1998, 12 (10) :1256.

[4]CHALASANI NP, HAYASHI PH, BONKOVSKY HL, et al.ACG Clinical Guideline:the diagnosis and management of idiosyncratic drug-induced liver injury[J].Am J Gastroenterol, 2014, 109 (7) :950-966.

[5]YIMER G, UEDA N, HABTEWOLD A, et al.Pharmacogenetic&pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients[J].PLo S One, 2011, 6 (12) :e27810.

[6]JONES M, NUNEZ M.Liver toxicity of antiretroviral drugs[J].Semin Liver Dis, 2012, 32 (2) :167-176.

[7]BJORNSSON ES, BERGMANN OM, BJORNSSON HK, et al.Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland[J].Gastroenterology, 2013, 144 (7) :1419-1425.

[8]MUGUSI S, NGAIMISI E, JANABI M, et al.Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenzbased HAART with or without tuberculosis co-infection in Tanzania[J].PLo S One, 2012, 7 (7) :e40180.

[9]WANG YL, QI YW, BAI JS, et al.Clinical analysis of drug induced liver disease in AIDS/HIV patients[J].J Kunming Med Coll, 2009, 30 (3) :129-132. (in Chinese) 汪亚玲, 祁燕伟, 白劲松, 等.AIDS/HIV药物性肝损伤的临床分析[J].昆明医学院学报, 2009, 30 (3) :129-132.

[10]FERNANDEZ-VILLAR A, SOPENA B, VAZQUEZ R, et al.Isoniazid hepatotoxicity among drug users:the role of hepatitis C[J].Clin Infect Dis, 2003, 36 (3) :293-298.

[11]COFFIE PA, TONWE-GOLD B, TANON AK, et al.Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women.MTCT-Plus program, Abidjan, C8te d'Ivoire[J].BMC Infect Dis, 2010, 10:188.

[12]SCHUTZ C, ISMAIL Z, PROXENOS CJ, et al.Burden of antituberculosis and antiretroviral drug-induced liver injury at a secondary hospital in South Africa[J].S Afr Med J, 2012, 102 (6) :506-511.

[13]TREEPRASERTSUK S, HUNTRAKUL J, RIDTITID W, et al.The predictors of complications in patients with drug-induced liver injury caused by antimicrobial agents[J].Aliment Pharmacol Ther, 2010, 31 (11) :1200-1207.

施引文献

资源附件(0)

访问统计